Molecular Imaging of Matrix Metalloproteinase in Atherosclerotic Lesions

Davies, 1985, Plaque fissuring: the cause of acute myocardial infarction, sudden death and crescendo angina, Br Heart J, 53, 363, 10.1136/hrt.53.4.363 Virmani, 2000, Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions, Arterioscler Thromb Vasc Biol, 20, 1262, 10.1161/01.ATV.20.5.1262 Virmani, 2006, Pathology of the vulnerable plaque, J Am Coll Cardiol, 47, C13, 10.1016/j.jacc.2005.10.065 Lendon, 1991, Atherosclerotic plaque caps are locally weakened when macrophages density is increased, Atherosclerosis, 87, 87, 10.1016/0021-9150(91)90235-U Galis, 1994, Increased expression of matrix metalloproteinase and matrix degrading activity in vulnerable regions of human atherosclerotic plaques, J Clin Invest, 94, 2493, 10.1172/JCI117619 Shah, 1995, Human monocyte-derived macrophage induce collagen breakdown in fibrous caps of atherosclerotic plaques, Circulation, 92, 1565 Sukhova, 1999, Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques, Circulation, 99, 2503, 10.1161/01.CIR.99.19.2503 Galis, 2002, Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly, Circ Res, 90, 251, 10.1161/res.90.3.251 Pasterkamp, 2000, Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery, Atherosclerosis, 150, 245, 10.1016/S0021-9150(99)00371-8 Brown, 1995, Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina, Circulation, 91, 2125, 10.1161/01.CIR.91.8.2125 Aikawa, 2001, An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro, Circulation, 103, 276, 10.1161/01.CIR.103.2.276 Aikawa, 1998, Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization, Circulation, 97, 2433, 10.1161/01.CIR.97.24.2433 Fukumoto, 2001, Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits, Circulation, 103, 993, 10.1161/01.CIR.103.7.993 Crisby, 2001, Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization, Circulation, 103, 926, 10.1161/01.CIR.103.7.926 Tahara, 2006, Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography, J Am Coll Cardiol, 48, 1825, 10.1016/j.jacc.2006.03.069 Deguchi, 2006, Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo, Circulation, 114, 55, 10.1161/CIRCULATIONAHA.106.619056 Fujimoto, 2007, Molecular Imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy, Circulation, 116 Hartung, 2007, Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions, Eur J Nucl Med Mol Imaging, 34, S1, 10.1007/s00259-007-0435-0 Schafers, 2004, Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo, Circulation, 109, r107, 10.1161/01.CIR.0000129088.49276.83 Kolodgie, 2003, Targeting of apoptotic macrophages and experimental atheroma with radiolabeled Annexin V: a technique with potential for noninvasive imaging of vulnerable plaque, Circulation, 108, 3134, 10.1161/01.CIR.0000105761.00573.50 Su, 2005, Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling, Circulation, 112, 3157, 10.1161/CIRCULATIONAHA.105.583021 Xue, 2001, Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo, J Med Chem, 44, 2636, 10.1021/jm010127e Van der Wal, 1994, Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology, Circulation, 89, 36, 10.1161/01.CIR.89.1.36 Moreno, 1994, Macrophage infiltration in acute coronary syndromes: implications for plaque rupture, Circulation, 90, 775, 10.1161/01.CIR.90.2.775 Varnava, 2002, Relationship between coronary artery remodeling and plaque vulnerability, Circulation, 105, 939, 10.1161/hc0802.104327 Welgus, 1990, Neutral metalloproteinases produced by human mononuclear phagocytes: enzyme profile, regulation and cellular differentiation, J Clin Invest, 86, 1496, 10.1172/JCI114867 Galis, 1995, Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases, Proc Natl Acad Sci U S A, 92, 402, 10.1073/pnas.92.2.402 Galis, 1998, N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy?, Circulation, 97, 2445, 10.1161/01.CIR.97.24.2445 Nikkari, 1995, Interstitial collagenase-1 (MMP-1) expression in human carotid atherosclerosis, Circulation, 92, 1393, 10.1161/01.CIR.92.6.1393 Li, 1996, Increased expression of 72-kd type IV collagenase in human aortic atherosclerotic lesions, Am J Pathol, 148, 121 Loftus, 2000, Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute disruption, Stroke, 31, 40, 10.1161/01.STR.31.1.40 Pasterkamp, 1998, The relation of arterial geometry with luminal narrowing and plaque vulnerability: the remodeling paradox, J Am Coll Cardiol, 32, 655, 10.1016/S0735-1097(98)00304-0 Prescott, 1999, Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice over expressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury, Ann N Y Acad Sci, 878, 179, 10.1111/j.1749-6632.1999.tb07683.x Luan, 2003, Statins inhibit secretion of metalloproteinase-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages, Arterioscler Thromb Vasc Biol, 23, 769, 10.1161/01.ATV.0000068646.76823.AE Bellosta, 1998, HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscler Thromb Vasc Biol, 18, 1671, 10.1161/01.ATV.18.11.1671 Galis, 2002, Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling, Circ Res, 91, 852, 10.1161/01.RES.0000041036.86977.14 Visse, 2003, Matrix metalloproteinases and tissue inhibitors of metalloproteinase: structure, function, and biochemistry, Circ Res, 92, 827, 10.1161/01.RES.0000070112.80711.3D Gough, 2006, Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice, J Clin Invest, 116, 59, 10.1172/JCI25074 Kai, 1998, Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes, J Am Coll Cardiol, 32, 368, 10.1016/S0735-1097(98)00250-2 Blankenberg, 2003, Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients cardiovascular disease, Circulation, 107, 1579, 10.1161/01.CIR.0000058700.41738.12 Eldrup, 2006, Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis, Circulation, 114, 1847, 10.1161/CIRCULATIONAHA.105.593483 Farb, 1996, Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death, Circulation, 93, 1354, 10.1161/01.CIR.93.7.1354